Cassava Sciences Inc vs McDonald's Corp — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while McDonald's Corp trades at $273.96 (market cap $193.70B). The key difference: McDonald's Corp is far larger — about 4056.5× Cassava Sciences Inc's market cap, and McDonald's Corp pays a 2.72% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MCD | |
|---|---|---|
Market Cap | $47.75M | $193.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $341.06 |
52-Week Low | $0.87 | $262.80 |
Enterprise Value | -$34.93M | $247.47B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.72% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →